Lead Inventors:
Richard Deckelbaum, M.D.;
Susan J. Vannucci, Ph.D.;
Yvon Carpentier, M.D.
Tech Ventures Reference: IR#s 1895 & 1926
Protection of organs after stroke with use of injection containing omega-3 emulsion:
There are no effective therapeutic interventions against cerebral hypoxia-ischemia due to stroke or cardiac arrest. Many experimental studies demonstrate protection with treatment before the insult, but are not effective if only administered after the event. Intravenous or intraperitoneal injection of omega-3-triglyceride containing fish oil emulsion has been shown effective in reducing brain damage when administered after a hypoxic-ischemic insult in a rodent animal model. It is proposed to utilize such injections in situation of cardiac, intestinal, and lung ischemia as well as brain.
Injection of omega-3 fatty acid after stroke to prevent cell death:
This invention describes a therapeutic intervention in the treatment of organ ischemia to prevent the cell death following the insult. The intervention is the injection of intravenous omega-3 fatty acid rich lipid emulsions. These emulsions have potential uses in medical situations which require rapid delivery of long chain unsaturated omega-3 fatty acids, i.e., EPA and/or DHA, to organs.
Applications:
• Prevent organ (brain, heart, kidney, spinal cord, lung, large or small intestine, and lower or upper limbs) death or injury precipitated by hypoxia-ischemia
• Reduce adverse cytokine production and cell death or tissue damage resulting from hypoxia-ischemia
• Treat surgical or percutaneous revascularization, unstable angina, transient cerebral ischemia or stroke and thrombotic disease, abdominal operations, multiple trauma, infections, impending or manifest sepsis, cachexia disease, angiographic procedures, preterm infants, excessive acute phase reactions, acute respiratory distress syndrome, cardiovascular complications of diabetes mellitus, severe bums, Raynaud's disease, conditions of ectopic fat deposition and omega-3 fatty acid deficiency in cell membranes
• Prevent or reduce organ lipid excess deposition and/or cell
Advantages:
• Administrate effective after the ischemic event or stroke
• No harmful side effects
• Rapid and efficient delivery of EPA and/or DHA to organ in acute medical emergencies
• Improved mouth-feel and storage stoability
Patent Status: Patent Pending (US20070149617A1, WO/2008/036353) ~ see links below.
Licensing Status: Available for Licensing and Sponsored Research Support
Publications: Y.A. Carpentier, M. Hacquebard, L. Portois, I.E. Dupont, R.J. Deckelbaum and W.J. Malaisse,
Am J Clin Nutr. 2010, 91(4):875-82.
C.M Simoens, R.J Deckelbaum, J.J Massaut and Y.A Carpentier,
Am J Clin Nutr. 2008, 88(2):282-8.
